Skip to main content
BMY logo

Bristol-Myers Squibb Company (BMY) Stock: Price, Forecast & Analyst Target

Bristol-Myers Squibb Company (BMY) — MoonshotScore 85/100 (Exceptional band), calculated Nov 18, 2026. Price $58.80 (+0.79%), as of the Nov 20, 2026 trading session; market cap $120B. Expected results Feb 4, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$58.80 +$0.46 (+0.79%) Market Cap $120B

Bristol-Myers Squibb Company · BMY · NYSE · Healthcare · Drug Manufacturers - General

Research dated 2026-09-12: Bristol Myers Squibb develops, licenses and commercializes medicines across oncology, hematology, cardiovascular care, immunology and neuroscience, with Eliquis and Opdivo anchoring product revenue. Its equity story depends on whether the wider portfolio can counter the contraction embedded in longer-range revenue expectations without weakening cash generation.

Price as of Nov 20, 2026

Key Statistics

85 of 100

MoonshotScore v2 · Bristol-Myers Squibb Company (BMY)

Exceptional
Business Quality Elite (92)
Financial Safety Okay (50)
Valuation Fair (63)
Growth Durability Growing (76)
Momentum Surging (81)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality and durable growth, though the balance sheet is only middling; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Fair; Growth Durability: Growing; Momentum: Surging.

  • EPS beat 0 of the last 4 reports
  • expected results Feb 4, 2027
  • Altman Z 2.67 · Piotroski F 7

Helping: business quality, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for BMY (58 recorded, newest six shown)
RecordedScoreBand
90Exceptional
90Exceptional
90Exceptional
85Exceptional
85Exceptional
85Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$58.80
Change on the day+0.79%
52-week range$45.27–$68.64
Market capitalisation$120B—
Price / earnings (trailing)13.57
Shares traded on the day12.63M
Beta (volatility vs the S&P 500)0.23

Why Bristol-Myers Squibb Company scores 85

Dr. Mira Sol, the Stock Expert AI TV data character
Business Quality carries the score; Financial Safety is what holds it back.
Dr. Mira Sol · Data scientist, Stock Expert AI TV (fictional AI character)
85Exceptional
  • Business Quality92
  • Financial Safety50
  • Valuation63
  • Growth Durability76
  • Momentum81

Share price, last 12 months +32.9%

$47.26 $62.80

What the price assumes

2.1% a year of free-cash-flow growth for ten years is what a $128.37B market value ( snapshot) asks for.

  • Price implies, next ten years2.1%
  • Free cash flow, last 5 years-0.7%
  • Revenue, last 5 years2.5%
  • Analysts' revenue path, 2026–2030-7.3%

The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint. It also runs ahead of the analysts' revenue path.

Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $9.29B. Inputs: FMP statements, estimates and quote.

How the stock reacts to earnings

EPS beat in 11 of the last 12 reports (2024–2026); the stock still fell the next session after 4 of those beats. Average first-session move: 4.5% either way.

  1. -1.4%Feb ’24
  2. -8.2%Apr ’24
  3. +8.2%Jul ’24
  4. +3.2%Oct ’24
  5. -4.8%Feb ’25
  6. -1.3%Apr ’25
  7. -3.8%Jul ’25
  8. +8.1%Oct ’25
  9. +7.6%Feb ’26
  10. +1.1%Apr ’26
  11. +3.5%Jul ’26
  12. +3.2%Oct ’26
Next-session move EPS beat (11) EPS in line (1)
Every report, with revenue and five-session moves
Moves run from the close before the report to the first and fifth closes after it.
ReportEPSRevenueNext session5 sessions
BeatBeat+3.2%+4.2%
BeatBeat+3.5%+1.7%
BeatBeat+1.1%-2.3%
BeatBeat+7.6%+3.9%
BeatBeat+8.1%+9.5%
BeatBeat-3.8%-1.3%
BeatBeat-1.3%+2.2%
BeatBeat-4.8%-6.3%
BeatBeat+3.2%+3.9%
BeatBeat+8.2%+7.7%
In lineBeat-8.2%-10.6%
BeatBeat-1.4%+2.3%

Beats have usually been rewarded — 7 of 11 drew a higher close the next session.

What management is saying differently

Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.

  • New this call: “long term”, “late stage”, “stage pipeline”, “christopher boerner” — none of them came up in Q2 FY2026.
  • Gone quiet: “phase iii”, “long-term growth”, “financial flexibility”, “forward-looking statements” — regular themes last call, absent this time.

The tone held steady from one call to the next; what changed is the subject matter, not the confidence.

Our track record on this stock

Since the score went from 89 to 85 while the share price moved -12.6% through .

MoonshotScore (0–100, band floors 45 · 65 · 80) Share price, scaled to its own range

The score has stayed in the Exceptional band across the stretch we have recorded; we grade each band change three months after it happens.

The crowd against our signals

  • Analysts: 45% of 42 rate it a buy; the average target sits +12.4% from the price of $58.80.
  • Last 90 days: 0 upgrades and 1 downgrade among 8 rating actions.
  • Our signals: Exceptional band; strongest pillar Business Quality (92), weakest Financial Safety (50).

Our signals are more constructive than the crowd, led by Business Quality.

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 20, 2026: low $44, high $67, latest $59. 4 reported quarters marked, 4 above and 0 below the recorded estimate. $67 $44 high $67 Feb 5, 2026 · Earnings results · reported above the recorded estimate · close $621Apr 30, 2026 · Earnings results · reported above the recorded estimate · close $582Jul 30, 2026 · Earnings results · reported above the recorded estimate · close $653Oct 29, 2026 · Earnings results · reported above the recorded estimate · close $624 Oct 17, 2025 Nov 20, 2026 · $59 $44Oct 17, 2025$46Oct 31, 2025$47Nov 14, 2025$49Nov 28, 2025$52Dec 12, 2025$55Dec 26, 2025$56Jan 9, 2026$55Jan 23, 2026$62Feb 6, 2026$61Feb 20, 2026$60Mar 6, 2026$57Mar 20, 2026$60Apr 2, 2026$60Apr 17, 2026$58May 1, 2026$57May 15, 2026$57May 29, 2026$57Jun 12, 2026$58Jun 26, 2026$58Jul 10, 2026$62Jul 24, 2026$65Aug 7, 2026$67Aug 21, 2026$67Sep 4, 2026$63Sep 18, 2026$61Oct 2, 2026$60Oct 16, 2026$62Oct 30, 2026$63Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Bristol-Myers Squibb Company (BMY): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Strong
Financial Safety Neutral
Valuation Moderate
Growth Durability Moderate
Momentum Strong

Legends Council

5 lenses, 5 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Moderate
Debt/Equity Negative
ROE Strong
Gross Margin Strong

Read on: Nov 21, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company less favourably than the MoonshotScore does: Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as undervalued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Bristol-Myers Squibb Company (BMY), and what does it report?

Short answer · as of

Bristol Myers Squibb sells medicines rather than generalized healthcare services.

Demand comes from the use of therapies such as Eliquis for clot and stroke prevention, Opdivo and Yervoy for cancer, Orencia for inflammatory disease, and Breyanzi for eligible lymphoma patients; distribution runs through wholesalers, pharmacies, hospitals, clinics and government organizations.

Reported revenue therefore measures a commercial drug portfolio with sharply different indications and treatment settings. Eliquis and Opdivo dominate the disclosed product view, while Orencia, Revlimid and Yervoy contribute smaller streams, so consolidated growth can conceal meaningful changes in the product mix.

2 · Latest results

What do the latest results show for Bristol-Myers Squibb Company (BMY)?

Revenue rebounded in the latest period and exceeded the recent range. Gross profit, operating income and net income rose more sharply than sales, while research spending also increased, showing stronger profit conversion without a retreat from development expense.

The earnings history shows an uninterrupted run of revenue and earnings results above consensus. That is an expectations observation rather than evidence of smooth underlying growth: annual revenue recently changed little while net income swung from a large loss to a substantial profit, and quarterly cash generation has remained uneven.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$13.07B Oct 29, 2026
Latest report · revenue estimate
$12.72B Oct 29, 2026
Latest report · revenue vs estimate
Above estimate Oct 29, 2026
Latest report · EPS vs estimate
Above estimate Oct 29, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Oct 29, 2026$13.07B$12.72B$1.3500$1.1000
Jul 30, 2026$12.97B$11.74B$2.0400$1.6000
Apr 30, 2026$11.49B$10.93B$1.5800$1.4200
Feb 5, 2026$12.50B$12.28B$1.2600$1.2300
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$12.22B$2.20B$1.08 (diluted)
Q4 FY2025$12.50B$1.09B$0.53 (diluted)
Q1 FY2026$11.49B$2.68B$1.31 (diluted)
Q2 FY2026$12.97B$3.32B$1.62 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Bristol-Myers Squibb Company (BMY)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Operations have generated positive cash throughout the reported quarterly series, with capital spending consuming a modest share of that inflow. Short-term liquidity covers near-term obligations, and the latest cash balance improved from the prior period.

Debt remains far above cash and investments, leaving Bristol Myers Squibb in a substantial net-debt position. The company-specific vulnerability is that Eliquis and Opdivo carry much of the disclosed product base; erosion in those franchises would have to be absorbed by other medicines while research spending and debt claims continue. Longer-range revenue estimates indicate that this replacement burden is already central to market expectations.

4 · What to check next?

What should you watch next at Bristol-Myers Squibb Company (BMY)?

Short answer · as of

The next earnings report is expected on Feb 4, 2027.

At the scheduled earnings release, watch whether revenue remains near its latest high, whether gross profit continues to translate into operating income, and whether reported revenue and earnings again clear consensus. Research spending also deserves attention because the latest advance in profitability occurred alongside a higher development outlay.

Beyond the headline result, the useful test is product substitution: gains outside Eliquis and Opdivo need to become large enough to change the declining path embedded in longer-range estimates. Cash conversion should confirm the accounting result, while movement in cash relative to debt will show whether operating strength is improving financial flexibility.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Bristol-Myers Squibb Company compare with its peers?

Short answer

Bristol-Myers Squibb Company's score ranks tied for 4th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Bristol Myers Squibb belongs with commercial biopharmaceutical portfolios rather than businesses valued mainly on research prospects. Its mix combines a major anticoagulant franchise, broad oncology medicines, immunology and hematology products, and an autologous cell therapy, supported by established revenue and operating cash flow.

Therapeutic breadth does not produce balanced economics. Eliquis and Opdivo still dominate disclosed product revenue, making Bristol Myers Squibb less a collection of equally weighted franchises than a mature commercial base funding the search for its eventual replacements.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Eli Lilly and Company (LLY) Same industry, near in market value$1351.12 Nov 19, 2026$1.20T98 5-pillar Nov 18, 2026
Vertex Pharmaceuticals Incorporated (VRTX) Named competitor$520.66 Nov 19, 2026$132B90 5-pillar Nov 18, 2026
Sanofi (SNY) Named competitor$46.06 Nov 19, 2026$111B87 5-pillar Nov 18, 2026
Bristol-Myers Squibb Company (BMY) — this page$58.80$120B85
AstraZeneca PLC (AZN) Same industry, near in market value$174.35 Nov 20, 2026$270B85 5-pillar Nov 18, 2026
Amgen Inc. (AMGN) Same industry, near in market value$438.82 Nov 19, 2026$237B84 5-pillar Nov 18, 2026
AbbVie Inc. (ABBV) Same industry, near in market value$283.54 Nov 19, 2026$501B83 5-pillar Nov 18, 2026
Johnson & Johnson (JNJ) Same industry, near in market value$267.14 Nov 19, 2026$643B83 5-pillar Nov 18, 2026
Novartis AG (NVS) Same industry, near in market value$151.22 Nov 19, 2026$286B82 5-pillar Nov 18, 2026
CVS Health Corporation (CVS) Named competitor$80.84 Nov 20, 2026$103B81 5-pillar Nov 18, 2026
GSK plc (GSK) Named competitor$47.76 Nov 20, 2026$95.7B77 5-pillar Nov 18, 2026
Gilead Sciences, Inc. (GILD) Same industry, near in market value$166.53 Nov 19, 2026$207B72 5-pillar Nov 18, 2026
Merck & Co., Inc. (MRK) Same industry, near in market value$132.81 Nov 19, 2026$327B69 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$41.00 – $78.00
Consensus target
$66.14
Median target
$66.00

Consensus record · Captured .

Measured against a quoted price of $58.80 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 5, 2026

Transactions
43
Identified insiders
14
Purchases
0
Sales
3
Other transactions
40

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held BMY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported BMY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Bristol-Myers Squibb Company (BMY)?

Read these with our analysis →

Common Questions About BMY (Healthcare)

The last 2 questions are answered from this page's own dated data, not from the research.

How dependent is Bristol Myers Squibb on Eliquis and Opdivo?

Eliquis and Opdivo are the dominant disclosed product revenue streams. Their scale gives Bristol Myers Squibb a large commercial base, but it also means weakness in either franchise would require meaningful offsets from the rest of the portfolio.

Can Breyanzi change Bristol Myers Squibb's business mix?

Breyanzi gives Bristol Myers Squibb exposure to autologous cell therapy for eligible lymphoma patients. The disclosed revenue mix remains led by Eliquis and Opdivo, so a broader economic shift would require specialty therapies such as Breyanzi to become much more consequential within the portfolio.

Why do Bristol Myers Squibb earnings move more than revenue?

Annual revenue recently remained nearly level while net income moved from a large loss to a substantial profit, and quarterly profit has also fluctuated more than sales. Research and commercial spending are large enough that changes below the revenue line can materially alter reported earnings.

What would improve Bristol Myers Squibb's declining revenue outlook?

Sustained growth from medicines outside Eliquis and Opdivo would need to offset pressure on the leading franchises. Confirmation would appear as a less concentrated product mix, resilient consolidated sales and continued cash generation despite ongoing research spending.

What is the BMY stock price today?

The last price recorded for Bristol-Myers Squibb Company (BMY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the BMY price target?

The analyst consensus price target for Bristol-Myers Squibb Company (BMY), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 42 figures on this page — 1 from SEC filings and earnings calls, 35 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Operating cash flow by quarter (USD millions); Analyst revenue and earnings estimates (average)
  • 1. What is Bristol-Myers Squibb Company (BMY), and what does it report?: Sector / industry (provider taxonomy); Business description; Revenue by segment
  • 2. What do the latest results show for Bristol-Myers Squibb Company (BMY)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Most recent periodic reports
  • 3. What are the financial strengths and risks for Bristol-Myers Squibb Company (BMY)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash against market value; Trailing twelve-month ratio set; Revenue by segment; Analyst revenue and earnings estimates (average)
  • 4. What should you watch next at Bristol-Myers Squibb Company (BMY)?: Next earnings report; Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands); Revenue by segment; Analyst revenue and earnings estimates (average); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash, investments and debt
  • 5. How does Bristol-Myers Squibb Company compare with its peers?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set
  • FAQ: How dependent is Bristol Myers Squibb on Eliquis and Opdivo?: Revenue by segment; Business description; Analyst revenue and earnings estimates (average)
  • FAQ: Can Breyanzi change Bristol Myers Squibb's business mix?: Business description; Revenue by segment
  • FAQ: Why do Bristol Myers Squibb earnings move more than revenue?: Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Trailing twelve-month ratio set
  • FAQ: What would improve Bristol Myers Squibb's declining revenue outlook?: Revenue by segment; Analyst revenue and earnings estimates (average); Operating cash flow by quarter (USD millions); Quarterly income statement (USD thousands)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold BMY

Funds in our ETF coverage that list BMY among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
iShares Evolved U.S. Innovative Healthcare ETF (IEIH)5.36%
Brookstone Value Stock ETF (BAMV)4.41%
Alger Russell Innovation ETF (INVN)2.71%
WisdomTree U.S. High Dividend Fund (DHS)2.51%
Pacer US Cash Cows 100 ETF (COWZ)2.21%
SPDV ETF2.05%
UVA Dividend Value ETF (UVDV)1.72%